Workshop Date and Time

Thursday, November 6, 2014, 1:30 – 2:30 pm, Eastern Time Register Now

Registrants can listen in live over the phone or online as a webcast.

Topics Covered

  • Mantle Cell Lymphoma Overview
  • Treatment Options for Newly Diagnosed
  • Treatment Options for Relapsed/Refractory Disease
  • Clinical Trials and Emerging Treatment Approaches
  • The Importance of Communicating with Your Health Care Team
  • Questions for Our Panel of Experts

Our Panel of Experts

Brad Kahl, MD
Skoronski Chair of Lymphoma Research, Associate Professor, University of Wisconsin School of Medicine and Public Health, Associate Director for Clinical Research, UW Carbone Cancer Center
Michael E. Williams, MD, ScM
Byrd S. Leavell Professor of Medicine and Professor of Pathology, Chief, Division of Hematology and Oncology, Director, Hematologic Malignancies Section, University of Virginia Health System
Anita Welborn, MSW
Senior Director, Patient Education and Services, Lymphoma Research Foundation
Carolyn Messner, DSW, MSW, OSW-C
Director of Education and Training, CancerCare

Continuing Education Credits

This program has been submitted for 1.0 Contact Hour to social workers by The University of Texas MD Anderson Cancer Center, an approved provider through the Texas State Board of Social Work Examiners, provider #CS4607. This program has been submitted to the Commission on Dietetic Registration for one Continuing Professional Education Unit (CPEU). All paperwork for CEU credit must be submitted within two weeks of the live program.

Brochure

You can download the brochure for this workshop (pdf) (85.2 KB)

Find More Connect Workshops

Browse by Diagnosis

Browse by Topic

The information presented in this workshop is provided for your general information only. It is not intended as medical advice and should not be relied upon as a substitute for consultations with qualified health professionals who are aware of your specific situation. We encourage you to take information and questions back to your individual health care provider as a way of creating a dialogue and partnership about your cancer and your treatment.